Trials / Completed
CompletedNCT04439526
A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis
Observational Study on GUselkumab: Effectiveness and Impact on quaLity of LIfe in naïVE or Bio Experienced Patients With Regional (Facial and Genital) Psoriasis (GULLIVER Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 356 (actual)
- Sponsor
- Janssen-Cilag S.p.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effectiveness profile of guselkumab used in a real-life setting in participants with moderate facial and/or genital psoriasis. Effectiveness will be evaluated using the static Physicians Global Assessment (sPGA) for the facial region and the sPGA for the genital region.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Guselkumab | Participants with moderate facial and/or genital psoriasis treated with guselkumab (as prescribed by their physician) in real world practice will be observed in this study. |
Timeline
- Start date
- 2020-06-10
- Primary completion
- 2023-11-21
- Completion
- 2023-11-21
- First posted
- 2020-06-19
- Last updated
- 2024-01-05
Locations
38 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT04439526. Inclusion in this directory is not an endorsement.